WT1 Expression in Peripheral Blood at Diagnosis and During the Course of Early Consolidation Treatment Correlates With Survival in Patients With Intermediate and Poor-Risk Acute Myeloid Leukemia
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F20%3A10418633" target="_blank" >RIV/00216208:11110/20:10418633 - isvavai.cz</a>
Alternative codes found
RIV/00023736:_____/20:00013103
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=2r7cKlZjBh" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=2r7cKlZjBh</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.clml.2020.07.014" target="_blank" >10.1016/j.clml.2020.07.014</a>
Alternative languages
Result language
angličtina
Original language name
WT1 Expression in Peripheral Blood at Diagnosis and During the Course of Early Consolidation Treatment Correlates With Survival in Patients With Intermediate and Poor-Risk Acute Myeloid Leukemia
Original language description
Dynamics of WT1 expression during the course of chemotherapy was tested in 106 cases of intermediate and high-risk acute myeloid leukemia in peripheral blood. High WT1 expression after 2 cycles of chemotherapy was a significant prognostic factor for overall and event-free survival in the whole cohort, as well as in patients treated without allogeneic stem cell transplantation. Background: Up to 55% of non-APL acute myeloid leukemias (AML) lack a molecular target suitable for standardized disease monitoring. We aimed to evaluate the prognostic significance of WT1 gene expression at early stages of intensive treatment. Patients and Methods: A total of 10(6) consecutive patients with intermediate and high-risk AML who had WT1 expression at diagnosis >500 copies/10(4) ABL and who achieved remission after 1 to 2 cycles of induction treatment were analyzed. WT1 expression was measured in peripheral blood using a standardized European LeukemiaNet method. Overexpression was defined as >50 copies/10(4) ABL. The median follow-up was 30 months. Results: Patients with normal versus high WT1 expression after 2 cycles of chemotherapy had overall survival (OS) at 3 years of 66% versus 41% (P=.01); event-free survival (EFS) 45% versus 22% (P=.01). Prognostic significance of WT1 expression after 2 cycles of treatment was maintained in the group of patients treated with chemotherapy alone without hematopoietic stem cell transplantation in first line treatment (OS 70% vs. 36%, P=.02; EFS 35% vs. 0%, P=.03). Significant prognostic factors for EFS on multivariate analysis were the achievement of molecular remission (<50 copies of WT1) at any time during treatment (hazard ratio [HR] 0.47, P=.04) and increased WT1 expression after 2 cycles of chemotherapy (HR 2.0, P=.03). Conclusion: Increased WT1 expression after 2 cycles of chemotherapy is a negative prognostic factor for survival. WT1 remains a valuable molecular marker in AML without any leukemiaspecific mutation, especially if next generation sequencing and/or digital polymerase chain reaction are not routinely available.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Clinical Lymphoma, Myeloma & Leukemia
ISSN
2152-2650
e-ISSN
—
Volume of the periodical
20
Issue of the periodical within the volume
12
Country of publishing house
US - UNITED STATES
Number of pages
12
Pages from-to
"e998"-"e1009"
UT code for WoS article
000593321200009
EID of the result in the Scopus database
2-s2.0-85090066450